Regulatory Partner NDA Group is a regulatory affairs and drug development consultancy with a long-standing track record in global filings and approvals, presenting a clear opportunity to sell end-to-end regulatory strategy services to biotech startups and established players looking to expand into new markets.

Strategic Synergy As part of SSI Strategy, NDA Group combines regulatory proficiency with clinical development, medical affairs and commercial planning, creating a holistic value proposition that can cross-sell advisory services to biotech portfolios seeking accelerated asset value realization.

Acquisition Momentum Recent acquisition by SSI Strategy signals strong market validation and potential for integrated service suites; sales outreach can leverage the credibility and expanded geographic reach resulting from this corporate growth.

Leadership Expansion New appointments to advisory boards and leadership roles indicate ongoing governance strengthening and subject-matter expansion, offering opportunities to position specialized consulting for oncology, internal medicine, and haematology segments.

Growth Signals Revenue range and mid-size employee base align with high-touch, expert services rather than large-scale outsourcing, suggesting a focus on premium regulatory strategy, dossiers, and market access support for mid-stage biotech and specialty pharma players.